credence research inc n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Glioblastoma Multiforme Market- Growth, Share, Opportunities, Competitive Analysis, and Forecast 2016 – 2023 PowerPoint Presentation
Download Presentation
Glioblastoma Multiforme Market- Growth, Share, Opportunities, Competitive Analysis, and Forecast 2016 – 2023

Loading in 2 Seconds...

play fullscreen
1 / 3

Glioblastoma Multiforme Market- Growth, Share, Opportunities, Competitive Analysis, and Forecast 2016 – 2023 - PowerPoint PPT Presentation


  • 1 Views
  • Uploaded on

The latest market report published by Credence Research, Inc. “Global Glioblastoma Multiforme\nMarket- Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 -\n2022,” the glioblastoma multiforme market was valued at USD 352.2 Mn in 2015

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Glioblastoma Multiforme Market- Growth, Share, Opportunities, Competitive Analysis, and Forecast 2016 – 2023' - amanj111


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
credence research inc

Credence Research Inc.

“Glioblastoma Multiforme Market- Growth, Share, Opportunities,

Competitive Analysis, and Forecast 2016 – 2023”

Buy Now

Sample Request

E-mail: sales@credenceresearch.com

Ph: 1-800-361-8290

Web: http://www.credenceresearch.com

request sample

Request Sample

The latest market report published by Credence Research, Inc. “GlobalGlioblastoma Multiforme

Market- Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 -

2022,” the glioblastoma multiforme market was valued at USD 352.2 Mn in 2015, and is expected to

reach USD 898.9 Mn by 2022, expanding at a CAGR of 10.95% from 2016 to 2022.

Browse the full report Glioblastoma Multiforme Market - Growth, Share, Opportunities,

Competitive

Analysis,

and

at http://www.credenceresearch.com/report/glioblastoma-multiforme-market

Market Insights

Glioblastoma multiforme (GBM) belongs to a group of brain tumors known as gliomas that grows

from a type of brain cell called a glial cell. It is the most common primary brain tumor in adults and

also the most aggressive form of brain tumor. According to U.S. National Cancer Institute, GBM is

considered as the most aggressive form of brain cancer which represents 15.4% of all primary brain

tumors and about 60% - 75% of all astrocytoma and shows rapid growth rate of benign cells in the

organ. According to World Health Organization (WHO), the incidence of glioblastoma multiforme

(GBM) is 2 to 3 per 100,000 people in the United States and Europe. Overall GBM accounts for 12 to

15% of all intracranial tumors and 50 to 60% of astrocytic tumors. In year 2015, temozolomide

accounted for the largest market share of the global glioblastoma multiforme market. The key

advantages possessed by temozolomide are delayed progression without impacting the quality of life

and less adverse effects compared to other molecules. Medical practitioners suggest that,

combination radiotherapy and temozolomide chemotherapy is currently the standard of care for most

patients suffering from GBM. On the other hand, the geographical analysis of glioblastoma

multiforme market projected North America and Europe as the dominant regions followed by Asia-

Pacific. The key factors driving the glioblastoma multiforme market include developed research and

development facilities, upcoming drug launches, rising incidences of the central nervous system

cancers in the geriatric population. Thus, upcoming drugs and ongoing research developments are

expected to drive the overall market og glioblastoma multiforme market across the globe.

Pipeline Analysis

The phase III drugs included in the pipeline analysis are TRC-105, VB-111, TOCA 511, DCVax-Brain,

Rindopepimut (CDX-110), and others. According to market experts, these upcoming drugs assure to

provide enhanced efficacy, shorter onset of action and fewer side effects as compared to the

currently available glioblastoma multiforme treatment. Large number of investigational molecules

belongs to immunotherapy category which is expected to change the overall perspective of the

market. Thus, future commercialization of these molecules during the forecast period 2016 – 2022 is

anticipated to have a reflective impact on the growth of the overall glioblastoma multiforme market.

Forecast,

2016

2022

request sample 1

Request Sample

Browse the full Glioblastoma Multiforme Market - Growth, Future Prospects and Competitive Analysis,

2017 – 2025 report at http://www.credenceresearch.com/report/glioblastoma-multiforme-market

Latest Reports:

http://www.credenceresearch.com/report/sulphur-recovery-technology-market

http://www.credenceresearch.com/report/uv-irradiation-cabins-market

About:

Credence Research is a worldwide market research and counseling firm that serves driving organizations,

governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with

making enduring enhancements to their execution and understand their most imperative objectives. Over almost

a century, we've manufactured a firm extraordinarily prepared for this task.

Media Contact

Name: Chris Smith

Address: 105 N 1st ST #429,

SAN JOSE, CA 95103 US

E-mail: sales@credenceresearch.com

Ph: 1-800-361-8290

Web: http://www.credenceresearch.com